MedTrace Logo

fMRI Study of Early Brain Injury in Systemic Lupus Erythematosus

NCT06226324 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2024-01-26

No results posted yet for this study

Summary

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple organs and systems. The central nervous system is one of the most commonly involved parts, and the involvement of the nervous system is called neuropsychiatric lupus, which is one of the most common complications of SLE and the main cause of death. Cognitive impairment and emotional disorders are the most common neuropsychiatric symptoms, with a prevalence of up to 80%. Studies have shown that the prevalence of NPSLE is between 37% and 95%. Compared with SLE patients, the mortality rate increases by three times. Early diagnosis and treatment play an important role in improving the quality of life of patients. fMRI has the advantages of non-invasive, in vivo and high repeatability, and can detect the brain function changes of patients early before the structural changes. This study uses fMR to compare the differences in brain function changes between SLE patients and healthy controls, explore the neuroimaging mechanism of brain injury, and provide reference for the early clinical intervene.

Conditions

Interventions

OTHER

neuropsychological test

The subjects were evaluated for memory, cognition, mood and sleep

Sponsors & Collaborators

  • The Affiliated Hospital of Inner Mongolia Medical University

    lead OTHER

Principal Investigators

  • Peng fei Qiao · The Affiliated Hospital of Inner Mongolia Medical University

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-06-30
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06226324 on ClinicalTrials.gov